Form 4: Astera Labs President and COO Sells Over 88,000 Shares Under Pre-Arranged Trading Plan

Astera Labs' President and COO, Sanjay Gajendra, sold 88,627 shares of common stock for approximately $8.7 million on June 4, 2025, through a pre-established Rule 10b5-1 trading plan.

Summary

• Sanjay Gajendra, President and COO, and a Director of Astera Labs, Inc. (ALAB), reported the sale of common stock.
• The transactions occurred on June 4, 2025, and were executed automatically pursuant to a Rule 10b5-1 trading plan adopted by Mr. Gajendra on November 30, 2024.
• A total of 88,627 shares of common stock were disposed of across three separate entries.
• The shares were sold at a weighted average price of $98.1094 per share, with prices ranging from $98.1000 to $98.2200.
• The total value of the shares sold amounts to approximately $8,694,000.
• Following these transactions, Mr. Gajendra directly beneficially owns 2,262,318 shares of common stock.
• Additionally, shares are held indirectly by three estate planning trusts: Trust 1 (5,988,404 shares), Trust 2 (724,257 shares), and Trust 3 (724,257 shares). Mr. Gajendra disclaims beneficial ownership of these trust-held securities, except to the extent of any pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the fact that it's under a pre-arranged 10b5-1 plan mitigates any negative interpretation. It's a routine liquidity event for an executive rather than a signal of lack of confidence in the company's future.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, which indicates a pre-scheduled transaction rather than a reaction to recent negative company news, providing transparency and reducing concerns about opportunistic insider selling.

Negatives

• The sale by a key executive and director reduces insider ownership, which some investors may view as a slight negative, as it could be perceived as a reduction in management's direct stake in the company's future performance.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general implications of insider selling, which can sometimes be misinterpreted by the market if not understood as part of a pre-planned strategy.

Future Outlook

This Form 4 filing reports past transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2024.
• The Reporting Person disclaims beneficial ownership of the securities held by the estate planning trusts (Trust 1, Trust 2, Trust 3), except to the extent, if any, of his pecuniary interest therein.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a routine part of executive compensation and personal financial planning in publicly traded companies. Such filings provide transparency into changes in insider holdings but do not typically reflect new strategic or operational developments for the company.

Related Party Transactions

• Shares are held indirectly by three estate planning trusts (Trust 1, Trust 2, Trust 3) for which the Reporting Person is a trustee or has a relationship, though beneficial ownership is disclaimed except for pecuniary interest.

Stakeholder Impact

• Shareholders: The sale slightly reduces the direct ownership stake of a key executive, which is a common occurrence and generally not a significant concern when executed under a 10b5-1 plan.

Key Dates

Recommendation

Keywords

Astera Labs, ALAB, Form 4, insider trading, stock sale, Rule 10b5-1, Sanjay Gajendra, beneficial ownership, executive compensation